| Study Period | 2019 - 2032 |
| Market Size in 2025 | USD 10.3 Billion |
| Market Size in 2026 | USD 10.9 Billion |
| Market Size by 2032 | USD 16.3 Billion |
| Projected CAGR | 6.8% |
| Largest Country | Saudi Arabia |
| Fastest-Growing Country | UAE |
| Market Structure | Fragmented |
Explore the market potential with our data-driven report
The GCC precision medicine market size will be an estimated USD 10.3 billion for 2025, and it will grow by 6.8% during 2026–2032, to reach USD 16.3 billion by 2032.
The major factors responsible for the growth of the market include increasing prevalence of chronic diseases, rapidly advancing genomic research capabilities, rising government investments in healthcare transformation, and growing demand for personalized medical care across the Gulf Cooperation Council nations.
The surging burden of chronic diseases, particularly cancer and genetic disorders, is the key factor driving the adoption of precision medicine across the GCC region. According to the WHO reports each year, around 400,000 children and adolescents aged 0–19 are diagnosed with cancer worldwide, highlighting the significant impact of the disease across all age groups and the urgent need for continued advancements in early detection, treatment innovation, and precision-medicine approaches.
Moreover, the GCC governments are actively investing in healthcare infrastructure modernization and genomic research capabilities. For instance, under Saudi Arabia's Vision 2030, the Kingdom has allocated over USD 65 billion towards enhancing healthcare infrastructure, establishing medical cities, and promoting healthcare innovation. Similarly, the UAE’s National Cancer Control Plan emphasizes genomic research and precision oncology initiatives.
The therapeutics category holds the largest market share, of 45%, in 2025, attributed to the increasing adoption of targeted therapies, immunotherapies, and gene therapies in the region. Additionally, the rising use of pharmacogenomic (PGx) testing is helping clinicians tailor drug selection and dosing based on individual genetic profiles, further accelerating the demand for precision therapeutics. The growing emphasis on developing treatments tailored to individual genetic profiles, combined with successful clinical outcomes, drives continued investment in precision therapeutics.
The diagnostics category will have the highest CAGR, driven by rapid technological advancements in molecular diagnostics, increasing adoption of companion diagnostics for targeted therapies, and growing awareness about the importance of early disease detection. The integration of advanced diagnostic technologies, including NGS platforms and liquid biopsy systems, in major GCC healthcare centers supports this growth trajectory.
The types analyzed in this report are:
The hospitals category holds the largest market share, of 60%, in 2025, driven by their comprehensive infrastructure, access to diverse patient populations, and participation in clinical trials and research initiatives. Hospitals in the GCC region serve as primary centers for implementing precision medicine, equipped with advanced diagnostic technologies, specialized treatment facilities, and multidisciplinary teams capable of delivering personalized care.
The home care category will have the highest CAGR, of 7.0%, during the forecast period, reflecting the increasing preference for personalized healthcare delivery in comfortable settings. This trend is also supported by the rising availability of home-based genetic testing kits and remote genomic counseling, enabling patients to access personalized insights without visiting clinical facilities. The expansion of telemedicine capabilities, remote monitoring technologies, and home-based genetic testing services supports this growth. The COVID-19 pandemic accelerated the adoption of home-based healthcare services, establishing new care delivery models that continue to evolve.
The end users analyzed in this report are:
Drive strategic growth with comprehensive market analysis
Saudi Arabia holds the largest market share, of 40%, in 2025. This leadership position is primarily attributed to the Kingdom's Vision 2030 healthcare transformation initiatives, substantial government investments in healthcare infrastructure, and the establishment of specialized medical cities and genomic research centers.
According to the Saudi Cancer Registry, the Kingdom reported 24,470 new cancer cases in 2022, with global projections indicating that incidence could nearly double by 2040. This rising disease burden, combined with the high consanguinity rates in Saudi Arabia, commonly reported between 40% and 60%, which elevate the risk of inherited genetic disorders, is increasing the potential demand for precision-medicine solutions. The Kingdom's investment in developing local pharmaceutical manufacturing capabilities and attracting international biotechnology partnerships further strengthens its market position.
The establishment of 21 healthcare clusters across Saudi Arabia, coupled with health insurance expansion and privatization initiatives, creates an ecosystem conducive to precision medicine adoption. Major international collaborations, including partnerships with Johns Hopkins Medicine and Mayo Clinic, bring world-class expertise and accelerate the implementation of personalized medicine approaches.
UAE will have the highest CAGR, of 6.9%, driven by the Emirates' strategic positioning as a regional healthcare hub, significant investments in healthcare innovation, and proactive adoption of cutting-edge medical technologies.
The UAE government's commitment to precision medicine is exemplified by the 2023 National Cancer Control Plan, for genomic research and precision oncology initiatives. According to GLOBOCAN 2022 data, the UAE reported 5,526 new cancer cases, with breast cancer accounting for 20.7% of all cases, highlighting the need for personalized treatment approaches.
The Emirates' focus on establishing world-class healthcare infrastructure, including specialized cancer centers and genomic research facilities, positions it at the forefront of precision medicine adoption. The presence of international healthcare providers, favorable regulatory frameworks for clinical trials, and a strong medical tourism sector further accelerate market growth.
The countries of the market are as follows:
The market is fragmented due to the diverse mix of global leaders and regional participants operating across multiple components, genomics, molecular diagnostics, bioinformatics software, AI tools, targeted therapeutics, and clinical services. No single company offers an integrated, end-to-end precision medicine solution across the GCC, and adoption varies widely by country depending on national genomics programs, healthcare investment levels, and digital maturity. International companies like Illumina, Thermo Fisher Scientific, Roche, QIAGEN, and Siemens Healthineers compete alongside regional hospitals, diagnostic labs, research institutes, and government-backed initiatives. Additionally, procurement in GCC countries is influenced by local partnerships, regulatory differences, and individual government strategies, further preventing market consolidation.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages